TWO · 6549.TWO
TaiwanJ Pharmaceuticals Co., Ltd.
NT$6.79-NT$0.04 (-0.59%)
TaiwanJ Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.71% below the high.
Loading market information…
TWO · 6758.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 06:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
A-SPINE Asia Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
A-SPINE Asia Co., Ltd.’s forward annual dividend is NT$1.00 per share, paid annual. The forward yield is 3.34% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
A-SPINE Asia Co., Ltd. functions as a medical device enterprise, specializing in the entire cycle of research, development, production, and worldwide distribution of spinal implants and surgical instruments. The company's market presence spans numerous countries, including Taiwan, China, the Philippines, Australia, New Zealand, Iran, Vietnam, Indonesia, Spain, Trinidad, and Sri Lanka. Their product catalog features a variety of spinal stabilization systems, such as solutions for cervical anterior fixation, alongside thoracic and lumbar fixation devices. Additionally, A-SPINE Asia provides a comprehensive range of interbody fusion systems, encompassing ACDF, PLIF, TLIF, and ALIF cages. Its offerings further extend to balloon kyphoplasty and vertebral body replacement devices. Beyond its own manufactured products, the firm also acts as a distributor for a selection of imported orthopedic medical equipment. Established in 2001, A-SPINE Asia Co., Ltd. is based in New Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$6.79-NT$0.04 (-0.59%)
TaiwanJ Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.71% below the high.
NT$9.72+NT$0.15 (+1.57%)
Health & Life Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.97% below the high.
NT$12.60+NT$0.15 (+1.2%)
UniPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.25% below the high.
NT$11.70+NT$2.40 (+25.81%)
DuoGenic StemCells corporation’s quoted price sits in the lower half of its reported 52-week range, 45.58% below the high.
NT$6.97-NT$0.23 (-3.19%)
Sunder Biomedical Tech. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.4% below the high.
NT$7.78+NT$0.33 (+4.43%)
Pharmigene, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.35% below the high.
NT$16.60-NT$0.60 (-3.49%)
Welgene Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.43% below the high.
NT$14.40+NT$0.35 (+2.49%)
EPS Bio Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 22.16% below the high.
